Gastón Lucas Martinengo

机构：Centro Científico Tecnólogico - Rosario, Instituto de Oncología de Rosario

发表论文 12 篇 · 总被引 5206 次 · h-index 8

代表论文

• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019 · The Lancet · 被引 3392)
• Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer (2023 · New England Journal of Medicine · 被引 1144)
• Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial (2024 · The Lancet · 被引 298)
• Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study (2024 · Journal of Clinical Oncology · 被引 226)
• LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC) (2023 · Annals of Oncology · 被引 84)
• Efficacy and Safety of Nivolumab in Previously Treated Patients With Non–Small-cell Lung Cancer: Real World Experience in Argentina (2020 · Clinical Lung Cancer · 被引 23)